IP Library › Granted Patent US 10,046,079
Granted Patent B2
US 10,046,079 · App. 14/210,082 · Granted Aug 14, 2018

Clay composites and their applications

Inventors: Kausik Mukhopadhyay (College Park, MD); Krishnaswamy Kasthuri Rangan (Fairfax, VA); Tirumalai Srinivas Sudarshan (Vienna, VA)
A61L15/18A61L15/44A61L15/46A61L2300/402A61L2300/404
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,046,079
App. No.
14/210,082
Granted
Aug 14, 2018
Kind
B2
Abstract

Clay composite sheets, mats, films or membranes without polymers. Methods of preparing clay composite sheets, mats, films or membranes without using polymers in the method. Methods of using clay composite sheets, mats, films or membranes prepared without using polymers. Antimicrobial dressing having organo-modified clay product. Transdermal delivery of drugs using organo-modified clay product and methods.

Claims (15)

1. A polymer-free organo-modified free-standing antimicrobial transdermal clay film comprising a clay, a zwitter ion, and an antimicrobial agent, wherein the antimicrobial agent is selected from a group consisting of silver ion and silver-containing compounds, wherein the zwitter ion is selected from the group consisting of N,N,N-trimethylglycine and N,N,N-trimethylglycine hydrochloride, wherein the silver-containing compounds are selected from the group consisting of silver nitrate, silver oxide, and silver carbonate, and wherein the polymer-free organo-modified free-standing antimicrobial transdermal clay film is used for transdermal application.

2. The polymer-free organo-modified free-standing antimicrobial transdermal clay film of claim 1 , wherein the clay is selected from the group consisting of montmorillonite, kaolinite, smectite, and bentonite.

3. The polymer-free organo-modified free-standing antimicrobial transdermal clay film of claim 1 , wherein a thickness of the polymer-free organo-modified free-standing clay film ranges from about 1 micrometer to about 500 micrometer.

4. The polymer-free organo-modified free-standing antimicrobial transdermal clay film of claim 1 , wherein a thickness of the polymer-free organo-modified free-standing clay film ranges from about 1 micrometer to about 100 micrometer.

5. The polymer-free organo-modified free-standing antimicrobial transdermal clay film of claim 1 , wherein the polymer-free organo-modified free-standing clay film achieves a bending radius of curvature ranging from about 0.4 millimeter to about 10 centimeter.

6. The polymer-free organo-modified free-standing antimicrobial transdermal clay film of claim 1 , wherein the polymer-free organo-modified free-standing clay film has greater than 50% absorption of visible light.

7. The polymer-free organo-modified free-standing antimicrobial transdermal clay film of claim 1 further comprising an analgesic.

8. The polymer-free organo-modified free-standing antimicrobial transdermal clay film of claim 7 , wherein the analgesic is selected from the group consisting of opioid analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs) and adjuvant analgesics, capsaicin, clonidine, ketamine, Morphine, fentanyl, Buprenorphine and cannabinoids.

9. An antimicrobial dressing comprising the polymer-free organo-modified free-standing antimicrobial transdermal clay film of claim 1 .

10. A burn wound dressing comprising the polymer-free organo-modified free-standing antimicrobial transdermal clay film of claim 7 .

11. A polymer-free organo-modified free-standing antimicrobial transdermal clay film prepared by a method, the method comprising:

(a) mixing a clay particle and a zwitter ion solution to form a slurry;

(b) adding an antimicrobial agent to the slurry of step (a) to form a second slurry;

(c) casting the second slurry of step (b) on a substrate to form a third slurry casted on a substrate;

(d) drying the third slurry casted on the substrate of step (c) to obtain a dried product; (e) separating the dried product of step (d) to obtain the polymer-free organo-modified free-standing antimicrobial transdermal clay film, wherein the antimicrobial agent is selected from a group consisting of silver ion and silver-containing compounds, wherein the zwitter ion is selected from the group consisting of N,N,N-trimethylglycine and N,N,N-trimethylglycine hydrochloride, wherein the silver-containing compounds are selected from the group consisting of silver nitrate, silver oxide, and silver carbonate, and wherein the polymer-free organo-modified free-standing antimicrobial transdermal clay film is used for transdermal application.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2015
From: MUKHOPADHYAY, KAUSIK; RANGAN, KRISHNASWAMY KASTHURI; SUDARSHAN, TIRUMALAI SRINIVAS
To: MATERIALS MODIFICATION INC.
Reel/Frame 036879/0634 →
Continuity (2)
Provisional Application 61794420 · Mar 15, 2013
Related Publication 20140276484A1 · Sep 18, 2014
Cited By (2)
US 12,213,993 US 12,478,681